The pharmaceutical industry is no stranger to the challenging impact of COVID-19. With the rise on the demand and limiting the number of workforce with work from home arrangements, pharmaceutical distribution companies are starting to understand the COVID19 impact. These companies are approaching TEBillion to integrate business automation solutions for ensure ease and efficiency on their processes.
Amit Raina, SVP South East Asia announced this week that TEB is getting more inquiries from the pharmaceutical distribution companies the past few weeks and a couple of agreements are anticipated.
The rise on the demand with a limited number of workforce means that the pharmaceutical distribution companies need to be more certain as to how their sales processes are going that will allow them to have a more comprehensive view of how the pandemic has affected the company. This will ultimately help them make important business decisions.
TEBillion will provide cost-effective automation solutions with after sales support allowing the companies to be more flexible and adaptable during this pandemic.
For more information about TEBillion’s products and services, contact:
Email: pr@tebillion.email
Website: www.tebillion.com
About TEBillion: TEBillion is a business automation software solutions company headquartered in the UK. Born in 2018, TEBillion aims to make high growth businesses successful with over a hundred handpicked partners serving customers, worldwide
Let’s block ads! (Why?)
TOKYO, JAPAN - Media OutReach Newswire - 19 December 2025 – Exein, the European leader…
SEOUL, SOUTH KOREA - Media OutReach Newswire - 19 December 2025 – Exein, the European…
BANGKOK, THAILAND - Media OutReach Newswire - 19 December 2025 - Following the recent tablets…
CAIRO, EGYPT - Media OutReach Newswire - 19 December 2025 - OPPO today concluded the…
The Hong Kong Exporters’ Association Renews five-year agreement with the International Exhibition of Inventions Geneva…
NEW TAIPEI CITY, TAIWAN - Media OutReach Newswire - 19 December 2025 - The 2025…